Claims

1. A compound of the following structure:



,

or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1 for use in inhibiting growth of a tumor or cancer characterized by angiogenesis, invasion, or metastasis.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1 for use in the treatment of a tumor or cancer characterized by angiogenesis, invasion, or metastasis.

4. The compound or pharmaceutically acceptable salt thereof according to claim 1 for use in inhibiting growth of a tumor or cancer.

5. The compound or pharmaceutically acceptable salt thereof according to claim 1 for use in the treatment of a tumor or cancer.

6. A pharmaceutical composition comprising the compound of claim 1, or pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

7. Use of the compound of claim 1, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in the preparation of a medicament for the

treatment of a tumor or cancer characterized by angiogenesis, invasion, or metastasis in a subject, wherein the medicament is to be administered to the subject.

8. Use of the compound of claim 1, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in the preparation of a medicament for the treatment of a tumor or cancer in a subject, wherein the medicament is to be administered to the subject.

9. The use of claim 7 or 8, wherein the cancer or tumor is head and neck cancer, breast cancer, esophageal cancer, uterine cancer, ovarian cancer, colorectal cancer, endometrial cancer, gastric cancer, small bowel cancer, bladder cancer, or a sarcoma.

10. The use of claim 9, wherein the cancer or tumor is head and neck cancer.

11. The use of claim 10, wherein the head and neck cancer is squamous cell carcinoma of the head and neck (SCCHN).

12. The use of claim 10, wherein the head and neck cancer is adenoid cystic carcinoma.

13. The use of claim 9, wherein the cancer or tumor is breast cancer.

14. The use of claim 13, wherein the breast cancer is HER2-positive breast cancer.

15. The use of claim 13, wherein the breast cancer is HER2-negative breast cancer.

16. The use of claim 13, wherein the breast cancer is triple negative breast cancer.

17. The use of claim 9, wherein the cancer or tumor is colorectal cancer.

18. The use of claim 9, wherein the cancer or tumor is esophageal cancer.

19. The use of claim 18, wherein the esophageal cancer is esophageal adenocarcinoma.

20. The use of claim 9, wherein the cancer or tumor is uterine cancer.

21. The use of claim 9, wherein the cancer or tumor is ovarian cancer.

22. The use of claim 9, wherein the cancer or tumor is a sarcoma.

23. The use of claim 22, wherein the sarcoma is uterine sarcoma, fibrosarcoma, synovial sarcoma, soft tissue sarcoma, or angiosarcoma.

24. The use of claim 9, wherein the cancer or tumor is gastric cancer.

25. The use of claim 9, wherein the cancer or tumor is small bowel cancer.

26. The use of claim 25, wherein the small bowel cancer is small bowel adenocarcinoma.

27. The use of claim 9, wherein the cancer or tumor is bladder cancer.

28. The use of claim 27, wherein the bladder cancer is urothelial cancer.

29. The use of claim 27, wherein the bladder cancer is urothelial carcinoma.

30. The use of claim 9, wherein the cancer or tumor is endometrial cancer.

31. The use of any one of claims 7-30, wherein the subject is to be further treated with radiation therapy.

32. The use of any one of claims 7-31, wherein the subject is to be further treated with a Programmed Death 1 protein (PD-1) antibody.

33. The use of any one of claims 7-31, wherein the subject is to be further treated with a Programmed Death L1 protein (PD-L1) antibody.

34. The use of any one of claims 7-31, wherein the subject is to be further treated with an anti-EGFR (epidermal growth factor receptor) antibody.

35. The use of claim 34, wherein the subject is to be further treated with an anti-EGFR (epidermal growth factor receptor) monoclonal antibody (mAb).

36. The use of claim 34 or 35, wherein the cancer or tumor is head and neck cancer.

37. The use of claim 36, wherein the head and neck cancer is squamous cell carcinoma of the head and neck (SCCHN).

38. The use of any one of claims 35-37, wherein the anti-EGFR (epidermal growth factor receptor) mAb is cetuximab.

39. The use of any one of claims 7-31, wherein the subject is to be further treated with an HER2 (human epidermal growth factor receptor) antibody.

40. The use of claim 39, wherein the subject is to be further treated with an HER2 (human epidermal growth factor receptor) mAb.

41. The use of claim 39 or 40, wherein the cancer or tumor is breast cancer.

42. The use of claim 40 or 41, wherein the HER2 (human epidermal growth factor receptor) mAb is trastuzumab.

43. Use of the compound of claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of HER2-negative breast cancer or squamous cell carcinoma of the head and neck (SCCHN) in a subject, wherein the medicament is to be administered to the subject.

44. The use of any one of claims 7-43, wherein the subject is to be further treated with surgery.

45. The use of any one of claims 7-44, wherein the subject is a human.